ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1362	National Cancer Institute	Html	en	Hot Flashes and Night Sweats (PDQ®)–Health Professional Version	Expert-reviewed information summary about causes and treatment of hot flashes and night sweats in cancer patients.	hot flash scores 0.45918 tamoxifen-induced hot flashes 0.487401 Loprinzi CL 0.545839 menopausal symptoms 0.464059 Barton DL 0.475444 nocturnal hot flashes 0.494473 black cohosh 0.488248 androgen deprivation therapy 0.448869 clinical trial 0.448391 breast cancer treatment 0.460098 breast cancer patients 0.474226 postmenopausal breast cancer 0.456276 hot flashes merits 0.487946 Natl Cancer Inst 0.459556 breast cancer survivors 0.509665 North Central Cancer 0.472407 hot flash reduction 0.458714 hot flashes 0.905213 hormone replacement therapy 0.476539 et al. 0.506432 women 0.50642 core body temperature 0.45737 night sweats 0.457026 study 0.456946 stage breast cancer 0.454333	hot flash studies 0.449594 hot flushes 0.465978 breast cancer diagnosis 0.451556 postmenopausal hot flashes 0.500892 breast cancer recurrence 0.47207 hot flash management. 0.448239 PUBMED Abstract 0.549613 Cancer Res Treat 0.462211 nighttime hot flashes 0.501942 hot flash frequency 0.50736 menopausal hot flashes 0.487616 Cancer Treatment Group 0.476248 hot flash management 0.49365 postmenopausal women 0.477394 breast cancer risk 0.486953 Clin Oncol 0.505954 receptor–positive breast cancer 0.451466 breast cancer 0.743246 randomized controlled trial 0.545918 hot flash 0.591793 healthy postmenopausal women 0.454945 prostate cancer 0.455636 placebo-controlled trial 0.450402 Central Cancer Treatment 0.476295	CLICK HERE
1452	National Cancer Institute	Html	en	Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version	Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking.	smoking cessation strategy 0.633721 smoking cessation rates 0.605741 quit attempt 0.552085 effective smoking cessation 0.580922 gradual cessation group 0.483049 abrupt cessation 0.562882 prolonged validated smoking 0.480554 lung cancer 0.658405 tobacco cessation 0.463262 smoking cessation pharmacotherapies 0.597527 abrupt smoking cessation 0.601297 pipe tobacco smoking 0.505275 current smoking 0.475722 gradual cessation arm 0.465437 nicotine replacement therapy 0.54532 randomized trial 0.492165 Smoking cessation counseling 0.609156 receptor partial agonist 0.460896 area-level smoking prevalence 0.513667 smoking reduction 0.49426 smoking behavior 0.469981 smoking cessation treatment 0.588411 smoking prevalence data 0.513642 tobacco products 0.485537	abrupt cessation arm 0.472163 smoking cessation 0.926558 vs abrupt cessation 0.475821 adult cigarette smoking 0.474818 gradual cessation method 0.466403 cigarette smoking cessation 0.573293 cigarette smoking 0.62168 smoking cessation pharmacotherapy 0.595082 varenicline 0.542592 tobacco smoking 0.505702 smoking cessation rate. 0.602815 gradual cessation 0.501212 abrupt cessation group 0.489713 nicotinic acetylcholine receptor 0.464069 self-reported smoking abstinence 0.502629 smoking abstinence 0.574891 cigarette smoking prevalence 0.566333 randomized controlled trial 0.482431 6-month cessation rates 0.474432 nicotine patch 0.531368 smoking cessation intervention 0.590903 usual smoking patterns 0.480697 lung cancer mortality 0.510576 varenicline group 0.534998	CLICK HERE
1610	National Cancer Institute	Html	en	Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version	Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are composed of three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). Learn about the clinical features and treatment of these leukemias.	JMML 0.47142 5-year estimated probability 0.444988 evidence 0.458611 host disease grade 0.440441 anemia supervenes 0.445725 various chemotherapy regimens 0.572089 platelet-derived growth factor 0.511436 Leukemia Group 0.448642 white blood cells 0.44993 Myelodysplastic/ Myeloproliferative Neoplasms 0.440718 CMML 0.717566 marrow stem cell 0.463204 myelomonocytic leukemia 0.462437 HLA-matched unrelated individuals 0.444789 toxic effects 0.442066 bone marrow aplasia 0.560704 chronic myelomonocytic leukemia 0.449424 transplant-related mortality 0.457149 World Health Organization 0.564993 erythropoietic growth factors 0.554859 median age 0.543021 level 0.460994 randomized trial 0.458448 patients 0.901262 monthly maintenance 0.44579	randomized clinical trial 0.484352 major defining feature 0.454521 complete remission 0.448646 proliferative features 0.448887 DNA methyltransferase 0.449167 et al. 0.534469 young MDS patients 0.511634 follow-up study 0.441281 Complete hematologic remissions 0.570636 JMML leukemia cells 0.462656 pyrimidine-analog antimetabolite 0.44631 stem cell 0.531211 single-agent therapy 0.444312 13-cis retinoic acid 0.524469 transfusion requirements 0.448178 Median actuarial survival 0.504944 median duration 0.676959 nucleoside azacitidine 0.478539 particularly poor prognosis. 0.444869 patient survival data. 0.445943 bone marrow 0.729115 total-body radiation therapy 0.553338 allogeneic stem cell 0.441128 Juvenile myelomonocytic leukemia 0.458499	CLICK HERE
1927	National Cancer Institute	Html	es	Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil.	siguientes procedimientos 0.539535 células madre 0.949818 estadio iv 0.500925 adultos jóvenes 0.452563 órgano cercano.ampliar linfoma 0.561365 siguientes elementos 0.448931 sudores nocturnos 0.484622 faja ajustadora 0.430459 siguientes especialistas 0.43177 siguientes tipos 0.443725 vía oral 0.419326 rayos x 0.473568 Hodgkin Lymphoma 0.582459 abdomen).ampliar linfoma 0.535694 detecte.ampliar exploración 0.434601 enlace drugs approved 0.498183 escáner tep 0.492453 niño ayuda 0.424524 estadio iiies 0.760474 riesgo intermedio 0.462626 efectos tardíos 0.664689 estadio ie 0.575058 células anormales.ampliar aspiración 0.485872	PDQ Efectos tardíos 0.461638 National Cancer Institute 0.420283 sustancia quizás 0.427861 siguientes lugares 0.433237 siguientes riesgos 0.418851 Instituto Nacional 0.434896 PDQ Tratamiento 0.682769 estadio iie 0.500587 Hodgkin recién 0.557678 explorador tep 0.443167 estadio e 0.45134 nuevos tipos 0.421275 Physician Data Query 0.471298 posibles efectos 0.420063 infancia quizás 0.428464 estadio iiis 0.959473 ósea fabrica glóbulos 0.493208 pelvis.ampliar imágenes 0.420331 distinta intensidad 0.419212 almacena células 0.485736 siguientes pruebas 0.485604 siguientes estadios 0.440037	CLICK HERE
2114	National Cancer Institute	Html	es	Exámenes de detección del cáncer de hígado (hepatocelular) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de hígado (hepatocelular).	hepatitis c 0.799278 PDQ Exámenes 0.723065 estudio marcadores 0.652784 siguientes efectos 0.659695 Physician Data Query 0.826748 Estados Unidos 0.932003 rayos x 0.659043 prevención revisa 0.639071 sustancias dañinas 0.671115	cuerpo usa 0.666699 ondas sonoras 0.6623 siguientes exámenes 0.740755 información ayuda 0.645281 National Cancer Institute 0.657644 siguientes riesgos 0.650336 siguientes sumarios 0.743208 Instituto Nacional 0.706872 múltiples funciones 0.667669	CLICK HERE
3523	National Cancer Institute	Html	es	Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos)	Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento.	Tumor Profiling 0.554625 estudio match 0.941659 Investigación Oncológica 0.6022 MD Anderson 0.61416 Memorial Sloan-Kettering Cancer 0.578519 Clinical Trials 0.539697 posibles participantes 0.607033 C2 MET 0.546519 Life Sciences 0.627896 laboratorios foundation medicine 0.56991 Foundation Medicine 0.623082 Memorial Sloan-Kettering identificarán 0.577406 estudio comet 0.807536 Grupo Cambio 0.537516 met amp crizotinib 0.576245	como los costos 0.539059 seguro médico 0.533808 Cancer Center 0.605302 MD Anderson Cancer 0.572606 tratamiento inscribirán 0.618222 sk crizotinib 0.541473 cabo estudios 0.534561 Caris Life Sciences 0.579205 Investigación Oncológica ECOG-ACRIN 0.571301 Memorial Sloan-Kettering 0.625566 egfr mut afatinib 0.573282 NRG Oncology Group 0.568484 Iniciativa de Medicina 0.538366 Life Sciences identificarán 0.57351	CLICK HERE
3571	National Cancer Institute	Html	en	The ALCHEMIST Lung Cancer Trials	A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.	alchemist immunotherapy trial 0.735513 eligible patients 0.582681 ALK gene change 0.625433 lung cancer growth 0.56975 Enrichment Marker Identification 0.526695 early-stage ALK-positive NSCLC 0.619613 lung cancer 0.910812 ALK gene alteration 0.615379 ALCHEMIST ALK Trial 0.709714 clinical trials 0.620441 early-stage lung cancer 0.567191 immunotherapy drug nivolumab 0.565565 ALCHEMIST EGFR Trial 0.638344 EGFR mutations 0.573101 patients 0.888179 usual treatment 0.573579 ALCHEMIST ALK treatment 0.711658 early-stage NSCLC 0.852776 ALK rearrangement 0.750976 matching placebo pill 0.62375 immunotherapy trial testing 0.582385 treatment trial 0.824243 Adjuvant Lung Cancer 0.576364 ALCHEMIST treatment trial 0.778098	radiation therapy 0.64065 randomized clinical trials 0.539654 standard treatment regimen 0.538133 ALCHEMIST 0.810249 ALK gene 0.692713 EGFR mutation 0.52844 early-stage squamous-type NSCLC 0.617402 advanced lung cancer 0.620145 early-stage EGFR-positive NSCLC 0.626895 ALK alterations 0.567183 treatment clinical trials 0.541011 alk treatment trial 0.714543 following research question 0.711662 ALK genetic rearrangement 0.647794 ALCHEMIST trials test 0.647386 lung cancer patients 0.596702 ALCHEMIST studies 0.5468 patient handout 0.660811 early-stage NSCLC patients 0.669994 ALCHEMIST EGFR treatment 0.639285 ALCHEMIST Screening Trial 0.627147 Immunotherapy Treatment Trial 0.587466 cell lung cancer 0.573239 ALCHEMIST trials 0.691377	CLICK HERE
14598	National Cancer Institute	Html	en	Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer	In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.	HIV-positive patients 0.653689 immune checkpoint inhibitor 0.461024 CD4-positive T-cell counts 0.58893 lung cancer 0.262982 clinical trials 0.487967 Cancer Immunotherapy Trials 0.394662 cells/mcL blood 0.306003 cancer care 0.278098 latent HIV 0.434111 specific safety evaluation 0.336765 protocol summary 0.256496 human immunodeficiency virus 0.379743 HIV researchers 0.432694 cancer agents 0.275507 checkpoint inhibitors 0.353273 NCI Center 0.275631 cancer studies 0.27424 immune system function 0.295428 new cancer treatments 0.395433 trial contact information 0.330052 antiretroviral therapy 0.544594 Dr. Thomas Uldrick 0.593112 cancer cells 0.448486 CD4-positive T-lymphocyte counts 0.343435	cytotoxic T lymphocytes 0.250726 Treating Patients 0.267044 cancer research 0.389529 pembrolizumab 0.349959 NCI Clinical Trials 0.352899 Dr. Uldrick 0.333877 immune function 0.289583 HIV-positive people 0.357305 T-cell inactivation 0.289834 Checkpoint inhibition 0.26775 T-cell activity 0.28158 refractory cancers 0.259957 combination antiretroviral therapy 0.352589 HIV-positive individuals 0.328061 immune dysfunction 0.583829 cancer endpoints 0.275484 AIDS Malignancy Branch 0.353274 people 0.402734 Disseminated Malignant Neoplasms 0.38833 CD4+ T cells/mcL 0.306067 immune attack 0.303915 HIV 0.902393 cancer 0.47424 tumor microenvironment 0.361786	CLICK HERE
15802	National Cancer Institute	Html	null	About the Blue Ribbon Panel	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.			CLICK HERE
17295	National Cancer Institute	Html	es	Estreñimiento	Información y consejos para controlar el estreñimiento, un efecto secundario del tratamiento del cáncer.	Coma alimentos 0.960932	efectos secundarios dañinos 0.717675	CLICK HERE